Free Trial
Don't Miss the A.I. Investing RevolutionStart Free For 30 Days

Eric Joseph Analyst Performance

Analyst at JPMorgan Chase & Co.

Eric Joseph is a stock analyst at JPMorgan Chase & Co. in the medical sector, covering 17 publicly traded companies. Over the past year, Eric Joseph has issued 14 stock ratings, including buy, hold, and sell recommendations. While full access to Eric Joseph's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eric Joseph's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
24 Last 6 Years
Buy Recommendations
58.33% 14 Buy Ratings
Companies Covered
17 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy58.3%14 ratings
Hold33.3%8 ratings
Sell8.3%2 ratings

Out of 24 total stock ratings issued by Eric Joseph at JPMorgan Chase & Co., the majority (58.3%) have been Buy recommendations, followed by 33.3% Hold and 8.3% Sell.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
94.1% of companies on NASDAQ
16 companies
NYSE
5.9% of companies on NYSE
1 company

Eric Joseph, an analyst at JPMorgan Chase & Co., currently covers 17 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
17 companies		100.0%

Eric Joseph of JPMorgan Chase & Co. specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
10 companies		58.8%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
3 companies		17.6%
MED INSTRUMENTS
1 company		5.9%
MED PRODUCTS
1 company		5.9%
MED - DRUGS
1 company		5.9%
PHARMACEUTICAL PREPARATIONS
1 company		5.9%

Eric Joseph's Ratings History at JPMorgan Chase & Co.

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export to Excel
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
10/9/2025Lower Price Target$25.53$46.00Overweight
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
6/3/2025Boost Price Target$43.13$64.00Overweight
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
5/20/2025Reiterated Rating$1.34Neutral
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
5/9/2025Lower Price Target$6.97$44.00Overweight
Novavax, Inc. stock logo
NVAX
Novavax
5/9/2025Lower Price Target$5.99$7.00Underweight
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5/7/2025Lower Price Target$36.19$67.00Overweight
OPKO Health, Inc. stock logo
OPK
OPKO Health
4/25/2025Initiated Coverage$1.46Neutral
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
3/31/2025Lower Price Target$47.86$75.00Overweight
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
3/14/2025Boost Price Target$55.17$78.00Overweight
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2/28/2025Lower Price Target$54.76$72.00Overweight
bluebird bio, Inc. stock logo
BLUE
bluebird bio
2/24/2025Upgrade$4.08Neutral
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2/10/2025Downgrade$7.79Neutral
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
1/29/2025Lower Price Target$19.56$30.00Overweight
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1/13/2025Upgrade$1.87Neutral
Today's Ratings
Top-Rated Stocks
More Ratings Tools